Search the Newsreel

Evogene Chairman Joins Company Results Call on August 18

Evogene Ltd. (EVGN) investors lift beneficial stake to 19.35% of shares

Evogene Ltd. shareholders, led by L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., have increased their beneficial ownership to 19.35% of the company's outstanding shares. This follows Pure Capital's open-market purchase of 533,088 additional American Depositary Shares (ADSs). The reporting persons collectively …

Evogene (EVGN) director Leon Recanati buys 460,000 shares and reports option holdings

Evogene Ltd. director Leon Recanati purchased 460,000 Ordinary Shares at $0.635 per share on August 11, 2026, increasing his direct holdings to 1,343,886 shares. The filing also disclosed his existing stock option awards with various exercise prices and expiration dates ranging from 2027 to …

Leon Recanati Discloses Investment at Evogene Ltd. with 5.7% Stake

Leon Recanati has disclosed a 5.7% stake in Evogene Ltd., acquiring 800,000 shares for approximately $400,000. This investment comes ahead of a contested director election at Evogene’s upcoming annual meeting on September 4, 2026. Recanati intends to support the current board of directors, citing …

Evogene (EVGN) director Leon Recanati buys 800,000 shares, lifts stake to 5.7%

Evogene director Leon Recanati has increased his stake in the company to 5.7% by purchasing 800,000 ordinary shares for approximately $400,000. This acquisition brings his total beneficial ownership to 894,836 shares and confirms his intention to vote in favor of the current board's director …

Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Evogene Ltd (EVGN) has an earnings forecast score of 8.00, placing it 171st out of 387 in its industry. Analysts have set an average price target of $2.50, with a consensus "Buy" rating based on one analyst. The company's expected revenue for the next …

Evogene Ltd. (EVGN) investor group boosts ownership to 15.98%

An investor group linked to L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman, and Ron Yair Peled has increased its stake in Evogene Ltd. (EVGN) to approximately 15.98% of the outstanding ordinary shares. This increase follows open-market purchases of 216,300 American …

Evogene Ltd. (EVGN) director boosts stake with 800,000-share buy

Evogene Ltd. director Leon Recanati significantly increased his direct ownership in the company by purchasing 800,000 Ordinary Shares on August 4, 2026, at a weighted average price of $0.50 per share. This transaction brings his total direct holdings to 883,886 Ordinary Shares. The insider …

Evogene Sets Sept. 4 AGM Amid Board Contest and VP Departure

Evogene Ltd. Revenue Breakdown – NASDAQ:EVGN

Evogene Ltd. (NASDAQ: EVGN) generated a total revenue of $3.85 million USD last year. The majority of this revenue, $2.17 million USD, came from its Industrial Applications segment, which was its top-performing segment. Geographically, Africa contributed the most, accounting for $2.04 million USD of …

Evogene (Nasdaq: EVGN) faces proxy slate battle and reverse split decision

Evogene (EVGN) is preparing for its 2026 annual general meeting where shareholders will vote on two competing board slates: the incumbent seven-member Evogene Slate and the four-member Pure Capital Slate. Key proposals also include increasing authorized share capital and approving a reverse share split …

EVGN|Evogene Ltd|Price:0.471|Chg%:-0.016

This article provides a comprehensive stock analysis of Evogene Ltd (EVGN) from TradingKey, highlighting its "fairly valued" status within the Biotechnology & Medical Research industry, high institutional ownership, and a "Buy" rating from analysts with a target price of $2.15. Despite healthy fundamentals and …

Evogene Ltd (EVGN) Valuation: PE, PB & Fair Value Analysis

Evogene Ltd (EVGN) currently holds a valuation score of 6.99, placing it 257th out of 384 companies in the Biotechnology & Medical Research industry. Its P/E ratio stands at -0.45, reflecting a significant deviation from its recent high and low P/E values. The company …

Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Evogene Ltd (EVGN), highlighting its current risk score of 2.88 and its ranking within the Biotechnology & Medical Research industry. It details EVGN's beta value of 1.36, indicating higher volatility compared to the S&P 500. The report …

Evogene Schedules Second Quarter 2026 Financial Results Release

Evogene Ltd. (Nasdaq: EVGN) announced it will release its financial results for the second quarter 2026 on Tuesday, August 18, 2026. Following the release, company management will host a conference call to discuss the results at 9:00 AM ET. Evogene is a computational chemistry …

Evogene Ltd (EVGN) Cash Flow

This article provides a detailed quarterly cash flow statement for Evogene Ltd (EVGN), including operating, investing, and financing activities, along with year-over-year percentage changes and specific monetary figures. It also defines and explains key cash flow metrics like operating cash flow, investing cash flow, …

Form 13D/A Evogene Ltd. For: 27 July By Investing.com

This article announces the filing of Form 13D/A by Evogene Ltd. on July 27. It is a brief news item from Investing.com, typical of filings news. The article provides the company name, the form filed, and the date of the filing.

Evogene Ltd. (EVGN) holders report 17.41% stake and new ADS buys

Evogene Ltd. shareholders, including L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., have collectively reported a 17.41% stake in the company through an amended Schedule 13D filing. This group, holding shared voting power over 2,252,000 ADSs and 56,100 Ordinary Shares, also acquired …

AI is rewiring future of energy crops - Ofer Haviv, CEO, Evogene (EVGN)

Ofer Haviv, CEO of Casterra (a subsidiary of Evogene), discusses how AI-driven gene-to-trait mapping and predictive breeding are transforming castor oil into a scalable biofuel feedstock. The article highlights castor's potential as a climate-resilient, low-input crop that can avoid food-versus-fuel conflicts, particularly in regions …

Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Evogene Ltd (EVGN), outlining major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional ownership trends over several quarters, and recent shareholder activity with specific dates and proportional changes. The data highlights key investors …

EVGN|Evogene Ltd|Price:0.542|Chg%:-0.006

Evogene Ltd (EVGN) closed at $0.542, down 1.16%, with a market cap of $5.65M. Although its fundamentals are healthy and growth potential high, with some analysts maintaining a "Buy" rating and a price target of $2.15, the stock is expected to trend down in …

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Evogene Ltd. and ELEO Inc. have announced a strategic collaboration to develop next-generation oral small-molecule PCSK9 pathway inhibitors for hyperlipidemia and cardiovascular diseases. This partnership combines Evogene's AI-driven ChemPass AI™ platform with ELEO's biological expertise to accelerate the discovery and validation of novel oral …

Evogene Ltd. (EVGN) Stock Price, News, Quote & History

This Yahoo Finance page provides a detailed overview of Evogene Ltd. (EVGN), a computational biology company operating in agriculture, human health, and industrial applications. It includes current stock price, historical performance data, key financial metrics, analyst ratings, and company news. The company is headquartered …

Evogene and ELEO partner on oral PCSK9 inhibitor development By Investing.com

Evogene and ELEO Inc. have formed a collaboration to develop oral small-molecule inhibitors for the PCSK9 pathway, targeting hyperlipidemia and cardiovascular diseases. Evogene will leverage its ChemPass AI platform for candidate design, while ELEO will contribute biological expertise and validation capabilities. This partnership aims …

Evogene stock trades quietly as genomics group leans on cash and recent revenue growth

Evogene, a small-cap genomics company, is navigating a path towards profitability by balancing modest revenue growth, tight operating costs, and reliance on its existing cash reserves. The company reported $4.5 million in revenue in 2023 with continued operating losses, supported by a cash balance …

Evogene (EVGN) investors add 202K ADSs, now hold 16.81% stake

L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., and related individuals have increased their beneficial ownership in Evogene Ltd. (EVGN) to approximately 16.81% of the company's share capital, following the purchase of an additional 202,000 American Depositary Shares (ADSs) by Pure Capital. The …

Activist investors target Evogene (NASDAQ: EVGN) board as ATM capacity rises

Evogene Ltd. (NASDAQ: EVGN) has increased the capacity of its at-the-market (ATM) offering by $361,613, bringing the total to $3,288,113. Concurrently, the company updated its risk factors to address an ongoing campaign by activist shareholders who filed a Schedule 13D on July 10, 2026, …

EVGN (Nasdaq: EVGN) raises at-the-market ordinary share offering to $3.29M

Evogene Ltd. (Nasdaq: EVGN) has increased its at-the-market ordinary share offering from $2.92 million to $3.29 million under its existing Form F-3 shelf registration with A.G.P./Alliance Global Partners. The company has already sold approximately $1.75 million in ordinary shares through this program. A.G.P. will …

Evogene Ltd. 6-K

This article provides details on Evogene Ltd.'s 6-K filing, indicating it's a current report (8-K) filed on July 17, 2026. The filing is available for viewing on SEC.gov, with the source document served from SEC EDGAR. MLQ.ai offers further research, news, and infrastructure related …

AgPlenus Launches Antifungal Potency Predictor, Expanding ChemPass AI for Ag Capabilities

AgPlenus, a subsidiary of Evogene Ltd., has introduced its Antifungal Potency Predictor (APP), a machine learning model designed to forecast the antifungal potency of small molecules from their chemical structures. This AI tool expands Evogene's ChemPass AI for Ag™ platform, enabling the prediction of …

EVGN Forecast — Price Target — Prediction for 2027

EVGN Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Weak Operating Performance - Earnings Cycle Report

Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN)